Global Innovative Platforms Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Global Innovative Platforms Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $0 | Jan 13, 2026 |
| FY2025 | Sep 30, 2024 | $0 | Jan 13, 2026 |
| FY2024 | Sep 30, 2023 | $0 | Dec 30, 2024 |
| FY2023 | Sep 30, 2022 | $0 | Aug 23, 2024 |
| FY2022 | Sep 30, 2021 | $0 | Mar 10, 2023 |
| FY2022 | Sep 30, 2020 | $0 | Mar 10, 2023 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($718.3K) | Jan 13, 2026 |
| FY2025 | Sep 30, 2024 | ($136.2K) | Jan 13, 2026 |
| FY2024 | Sep 30, 2023 | ($282.8K) | Dec 30, 2024 |
| FY2023 | Sep 30, 2022 | ($53.8K) | Aug 23, 2024 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($718.3K) | Jan 13, 2026 |
| FY2025 | Sep 30, 2024 | ($136.2K) | Jan 13, 2026 |
| FY2024 | Sep 30, 2023 | ($282.8K) | Dec 30, 2024 |
| FY2023 | Sep 30, 2022 | ($53.8K) | Aug 23, 2024 |
| FY2022 | Sep 30, 2021 | ($73.3K) | Mar 10, 2023 |
| FY2021 | Sep 30, 2020 | ($8.9K) | Mar 21, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $382.8K | Jan 13, 2026 |
| FY2025 | Sep 30, 2024 | $23.4K | Jan 13, 2026 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($560.7K) | Jan 13, 2026 |
| FY2025 | Sep 30, 2024 | ($87.4K) | Jan 13, 2026 |
| FY2024 | Sep 30, 2023 | ($234.8K) | Dec 30, 2024 |
| FY2023 | Sep 30, 2022 | ($53.6K) | Aug 23, 2024 |
| FY2022 | Sep 30, 2021 | $262 | Mar 10, 2023 |
| FY2021 | Sep 30, 2020 | ($164) | Mar 21, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $199.3K | Jan 13, 2026 |
| FY2025 | Sep 30, 2024 | $15 | Jan 13, 2026 |
| FY2024 | Sep 30, 2023 | $415 | Dec 30, 2024 |
| FY2023 | Sep 30, 2022 | $47.8K | Aug 23, 2024 |
| FY2022 | Sep 30, 2021 | $262 | Mar 10, 2023 |
| FY2021 | Sep 30, 2020 | $0 | Mar 21, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $11.6K | Jan 13, 2026 |
| FY2025 | Sep 30, 2024 | $33.2K | Jan 13, 2026 |
| FY2024 | Sep 30, 2023 | $364.4K | Dec 30, 2024 |
| FY2023 | Sep 30, 2022 | $130.5K | Aug 23, 2024 |
| FY2022 | Sep 30, 2021 | $29.2K | Mar 10, 2023 |
| FY2021 | Sep 30, 2020 | $6.6K | Mar 21, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $187.7K | Jan 13, 2026 |
| FY2025 | Sep 30, 2024 | ($33.1K) | Jan 13, 2026 |
| FY2025 | Sep 30, 2023 | ($364.0K) | Jan 13, 2026 |
| FY2024 | Sep 30, 2022 | ($82.7K) | Dec 30, 2024 |
| FY2023 | Sep 30, 2021 | ($28.9K) | Aug 23, 2024 |
| FY2022 | Sep 30, 2020 | ($6.6K) | Mar 10, 2023 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($1.26M) | Jan 13, 2026 |
| FY2025 | Sep 30, 2024 | ($537.2K) | Jan 13, 2026 |
| FY2024 | Sep 30, 2023 | ($401.0K) | Dec 30, 2024 |
| FY2023 | Sep 30, 2022 | ($118.2K) | Aug 23, 2024 |
| FY2022 | Sep 30, 2021 | ($64.4K) | Mar 10, 2023 |
| FY2021 | Sep 30, 2020 | $8.9K | Mar 21, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 0 | Jan 13, 2026 |
| FY2025 | Sep 30, 2024 | 0 | Jan 13, 2026 |
| FY2024 | Sep 30, 2023 | 0 | Dec 30, 2024 |
| FY2023 | Sep 30, 2022 | 0 | Aug 23, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 0 | Jan 13, 2026 |
| FY2025 | Sep 30, 2024 | 0 | Jan 13, 2026 |
| FY2024 | Sep 30, 2023 | 0 | Dec 30, 2024 |
| FY2023 | Sep 30, 2022 | 0 | Aug 23, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 44.48M | Jan 13, 2026 |
| FY2025 | Sep 30, 2024 | 33.75M | Jan 13, 2026 |
| FY2024 | Sep 30, 2023 | 619,085 | Dec 30, 2024 |
| FY2023 | Sep 30, 2022 | 619,085 | Aug 23, 2024 |
| FY2022 | Sep 30, 2021 | 619,085 | Mar 10, 2023 |
| FY2021 | Sep 30, 2020 | 619,085 | Mar 21, 2022 |